Sorted By:


Medicines in Development for Immuno-Oncology 2017 Report

PhRMA  |  Report

More than 240 immuno-oncology treatments in development are accelerating progress for patients with cancer. The rapid pace of scientific advances has helped usher in a new era of medicine for cancer patients over the last decade. Biopharmaceutical researchers’ understanding of the underlying biol...

List of 2017 Medicines in Development for Alzheimer's

PhRMA  |  Report

This report outlines the medicines in development for Alzheimer's Disease including the drug name, sponsor, indication and development phase.

2014 Economic Futures Report

PhRMA  |  Press Release

The report uniquely combines quantitative data with input from industry leaders, resulting in a more complete picture of the potential growth trajectories facing the industry.

Yet Another Misleading Report on Medicine Prices

PhRMA  |  Blog Post

The report also failed to acknowledge the tremendous benefit new innovative medicines provide to patients, the health care system and society.

PhRMA Statement on 2014 Special 301 Report

PhRMA  |  Press Release

PhRMA appreciates the fact that USTR has raised these concerns in the Report.

Hurricane Sandy Special Report

PhRMA  |  Report

PhRMA created Rx Response in the aftermath of Hurricane Katrina to help ensure the continued flow of medicine to patients following a major disaster....

PhRMA Statement on AARP Prescription Drug Report

PhRMA  |  Press Release

CMS reports that prescription drug spending is a small share of total health care cost growth, accounting for just 8 percent of cost growth in 2007, compared to 18 percent in 2002; other health services such as hospitals, doctors, nursing homes and administrative costs accounted for the other 92 percent.

New Report Shows How Supply Chain Shapes Brand-Name Medicine Prices

PhRMA  |  Press Release

View the full report here and patient examples here.

Without Significant Reforms 340B Will Continue to Grow As Uninsured Rate Declines

Chartpack  |  From Our Network

340B policies and structure require fundamental reform....

New Medicine Approvals 2015 Report

PhRMA  |  Report

In 2015, the Food and Drug Administration (FDA) approved 57 new drugs and therapeutic biologics. Of those, a record 45 medicines were approved by the Center for Drug Evaluation and Research (CDER), while 12 biologics were approved by the Center for Biologics Evaluation and Research (CBER). The ne...

Chart Packs

PhRMA  |  From PhRMA

Improving patient health is the primary goal of patient care and better access to treatments not only improves overall health outcomes but can also provide a source of savings to the healthcare system. By reducing spending on other non-drug medical expenses, me...

2017 State of Vaccines

PhRMA  |  Report

Download the report to learn more.

Prescription Medicines: International Costs in Context

PhRMA  |  Report

Our new Prescription Medicines: International Costs in Context explains how medicines benefit patients, health care systems, and the global economy. Advances in treatment are tacking some of the world’s greatest public health challenges. These treatments provide critical savings for health care s...

340B 101

PhRMA  |  Report

Download the deck to learn more about the 340B program....

PhRMA Statement on AARP Report

PhRMA  |  Press Release

The result is an overstatement of consumers’ actual costs for these medicines and there is a tremendous disparity between AARP’s report and the numerous independent analyses showing drug costs growing slowly.

PhRMA and National Osteoporosis Foundation Release Report on Medicines in Development for Osteoporosis

PhRMA  |  Press Release

View the full report here:

Understanding Medicare Part B Pocket Card

PhRMA  |  Report

Medicare Part B covers physician office visits, outpatient care, ambulance services and medical equipment. It also covers a subset of prescription medicines that are administered in a physician office or outpatient hospital, such as cancer medicines, vaccines and medicines for rheumatoid arthriti...

Prescription Medicines: Costs in Context

PhRMA  |  Report" width="595" height="485" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" allowf...

Medicines in Development for Vaccines 2016 Report

PhRMA  |  Report

Vaccines have played a critical role in reducing the threat, and in many cases eliminating any reported cases, of some of the world’s most devastating infectious diseases.

New Report: Alzheimer’s Research “Setbacks” Critical for Breakthroughs of Tomorrow

PhRMA  |  Press Release

To showcase the science driving Alzheimer’s research, PhRMA will host a live webcast on July 15 at 1:30 pm (EDT) to discuss the report’s findings.

Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.

PhRMA  |  Blog Post

Unfortunately, Australia is discouraging inventors from seeking injunctions to stop products that may violate a patent from entering the market.

PhRMA Statement on Special 301 Report

PhRMA  |  Press Release

Effective protection of IP is a critical element of meeting President Obama's objective of doubling US exports over the next five years.

BMJ clinical trial report misleading

PhRMA  |  Blog Post

  For example, the authors assert that only 67% of the reviewed studies were “timely” reported according to FDAAA standards.

Medicines in Development for Alzheimer's 2016 Report

PhRMA  |  Report

Today, more than 5 million Americans have Alzheimer’s disease. The disease devastates the minds of patients, creates substantial burdens for families and caregivers, and currently costs the health care system more than $200 billion a year. These sobering statistics are projected to get much worse...

New report highlights more than 250 vaccines in development

PhRMA  |  Blog Post

View the full report here.

You have reviewed the first 100 results out of 1009. Each page contains 25 results. You're on page 4.

prev 1 2 3 4 5 6 next